Efficacy and safety of long‐acting recombinant fusion protein linking factor <scp>IX</scp> with albumin in haemophilia B patients undergoing surgery

Recombinant factor IX fusion protein was well tolerated and effectively maintained haemostasis during and after surgery. Stable FIX activity was achieved with a prolonged dosing interval and reduced consumption compared to conventional or currently available long-acting recombinant FIX.